Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Teladoc Health, Inc.

$7.71

+0.13 (+1.65%)

F 17Pipeline Score Tools & Services · Commercial
Market Cap
909.82 M
EPS
-1.14
P/E Ratio
-4.47 $
Value Trade
35.38 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    613.85 M

  • R&D Expenses

    67.86 M

  • Operating CF

    9.52 M

  • Total Assets

    2.81 B

  • Total Liabilities

    1.47 B

  • Equity

    1.34 B

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Profitable

  • Cash Position

    750.74 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Apr 30, 2026
Overview
Volume
1.23 M
52 Week Range
4.40 - 9.77
% held by Insiders
2.56 %
% held by Institutions
77.87 %
Enterprise Value
1.17 B
Total Shares
180.36 M
Short %
15.46 %
Float Shares
179.28 M
Company Description
HQ: 155 E 44TH STREET, NEW YORK, N...
Employees:5,600
https://www.teladochealth.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
F17
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
—
rNPV / MCap
Top 14%
Micro Cap
(rank 779 of 905)
Percentile Rank
Teladoc Health, Inc. has significant pipeline risk (17/100).
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TDOC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Teladoc Health, Inc. (TDOC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TDOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TDOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TDOC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TDOC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TDOC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-310 0.00 0 0 - - - - - -
2026-07-310 0.00 0 0 - - - - - -
2026-07-310 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TDOC
Apr 29, 2026
TDOCGeneral

Teladoc Health Reports First Quarter 2026 Results

Teladoc Health reported its financial results for the first quarter of 2026, revealing a 2% decrease in revenue year-over-year, totaling $613.8 million. The company experienced a net loss of $63.8 million, although it reaffirmed its full-year financial outlook. The Integrated Care segment showed growth, while the BetterHelp segment faced a revenue decline. Adjusted EBITDA remained stable, reflecting the company's ongoing efforts to maintain financial performance amidst challenges.

Read more →
-TDOC
Apr 15, 2026
TDOCConferences/Events

Teladoc Health to Announce First Quarter 2026 Financial Results

Teladoc Health Inc. will announce its first quarter 2026 financial results on April 29, 2026, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can access the call via a dedicated phone line or through a live audio webcast.

Read more →
Competitive Position
How TDOC ranks across every disease it competes in
Competitive Position is a premium feature
See how TDOC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial